Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2000 Nov;59 Suppl 1(Suppl 1):i21-7.
doi: 10.1136/ard.59.suppl_1.i21.

Anti-interleukin 6 receptor antibody treatment in rheumatic disease

N Nishimoto  1 , T Kishimoto, K Yoshizaki
Affiliations
Review

Anti-interleukin 6 receptor antibody treatment in rheumatic disease

N Nishimoto et al. Ann Rheum Dis. 2000 Nov.

Abstract

Interleukin 6 (IL6) is a pleiotropic cytokine with a wide range of biological activities. IL6 transgene into mice gives rise to the abnormalities such as hypergammaglobulinaemia, thrombocytosis, infiltration of inflammatory cells into the tissues, mesangial cell proliferation of the kidney as well as splenomegaly and lymphadenopathy, which are predictable by the biological functions of IL6 shown in vitro. Continuous overproduction of IL6 is observed in patients with some immune-inflammatory diseases such as Castleman's disease and rheumatoid arthritis that are frequently associated with similar abnormalities to those of IL6 transgenic mice, strongly suggesting the involvement of IL6 in the human diseases. Successful treatment of the model animals for immune-inflammatory diseases with anti-IL6 receptor (IL6R) antibody thus indicates the possible application of IL6 blocking agents to treat the IL6 related immune-inflammatory diseases of humans. In this review, the new therapeutic strategy for Castleman's disease and RA using humanized antibody to human IL6 receptor, MRA, is discussed.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Schematic model of IL6 functions. IL6 is a pleiotropic cytokine with a wide range of biological activities.
Figure 2
Figure 2
Anti-IL6R antibody treatment suppressed the increase in serum IgG1 levels in IL6 transgenic mice. C57BL/6J human IL6 transgenic mice (tgm) were first intraveneously treated with 2 mg/body of rat antimouse IL6R antibody (MR16-1) at 4 weeks of age to induce tolerance to the mice against rat IgG, then subcutaneously treated with 100 µg/body twice weekly from 5 to 17 weeks of age. Serum IgG1 levels were analysed by ELISA.
Figure 3
Figure 3
Anti-IL6R antibody treatment inhibited the development of mesangial proliferative glomerulonephritis and lymphocytic interstitial pneumonia in IL6 transgenic mice. C57BL/6J human IL6 transgenic mice (tgm) were treated with rat antimouse IL6R antibody (MR16-1) similarly to that of figure 2. Left kidneys and lungs were removed and fixed with 20% neutral buffered formalin for histological examination.
Figure 4
Figure 4
Improvement in Castleman's disease by humanised anti-IL6R antibody treatment.
Figure 5
Figure 5
Improvement in RA by humanised anti-IL6R antibody treatment.
See this image and copyright information in PMC

References

    1. Blood. 1988 Jun;71(6):1759-63 - PubMed
    1. Arthritis Rheum. 1999 Aug;42(8):1635-43 - PubMed
    1. Cytokine. 1990 Sep;2(5):381-7 - PubMed
    1. Nature. 1986 Nov 6-12;324(6092):73-6 - PubMed
    1. J Immunol. 1988 Jan 15;140(2):508-12 - PubMed